Ascendis Pharma A/SASNDNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank7
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P7
Near historical low
vs 5Y Ago
-0.2x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-7.65%
2024-25.75%
20238.91%
202228.31%
202113.40%
202036.16%
201936.60%
201840.86%
201750.84%
201662.90%